<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01556646</url>
  </required_header>
  <id_info>
    <org_study_id>Bajaj 01720</org_study_id>
    <nct_id>NCT01556646</nct_id>
  </id_info>
  <brief_title>Effect of Tolvaptan on Cognitive Function in Cirrhosis</brief_title>
  <official_title>Effects of Tolvaptan on Cognitive Function, Brain Metabolism and Quality of Life in Hyponatremic Cirrhotics With Hepatic Encephalopathy: A Prospective Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hunter Holmes Mcguire Veteran Affairs Medical Center</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Otsuka America Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Hunter Holmes Mcguire Veteran Affairs Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hypothesis: Tolvaptan will improve cognitive function, brain edema and health-related quality
      of life in cirrhotic patients with hyponatremia
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Baseline assessment will include a

        1. battery of eight cognitive tests

        2. Health related quality of life

        3. MRI head evaluating MR spectroscopy and diffusion tensor imaging

      Patients will then be given tolvaptan 15-30mg qd for 14 days after which the tests will be
      repeated. During the first 3 days of tolvaptan administration, patients will be admitted and
      serum sodium will be drawn every 8 hours. 24 hr urine collection will also be performed.

      Between the initiation and end of tolvaptan, patients will be seen at least every 3-5 days in
      between.

      Participation will be terminated in case patients get transplanted or develop overt HE in
      between.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2011</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cognitive performance</measure>
    <time_frame>14 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Brain MR Spectroscopy</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brain Diffusion Tensor Imaging</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-related Quality of Life</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Cirrhosis</condition>
  <condition>Hepatic Encephalopathy</condition>
  <condition>Hyponatremia</condition>
  <arm_group>
    <arm_group_label>Tolvaptan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Open label study of tolvaptan. First 3 days as an inpatient then outpatient for the remainder of the study</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tolvaptan</intervention_name>
    <description>15 to 30mg qd titrated to sodium concentration</description>
    <arm_group_label>Tolvaptan</arm_group_label>
    <other_name>Samsca</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Cirrhosis diagnosed by liver biopsy or radiological evidence of nodular cirrhotic
             liver or varices on endoscopy or laboratory features (platelet count &lt;150,000 with an
             AST/ALT ratio &gt;1).

          -  History of HE controlled on lactulose and/or rifaximin

          -  Last HE episode &gt;2 months prior to enrollment and &lt;2 episodes within 6 months

          -  Mini-mental status exam score â‰¥25

          -  Serum sodium &lt;130mg/dl within the last 14 days and the day of enrollment

          -  Availability of a caregiver

          -  Able to undergo MR of the head

        Exclusion Criteria:

          -  Uncontrolled HE manifested by MMSE &lt;25

          -  Alcohol abuse within 3 months

          -  Illicit drug use within 3 months

          -  Psychoactive drug use other than regularly scheduled anti-depressants or methadone.

          -  Contraindication to MR examination (see attached MRI Safety Form)

          -  Placement of a transjugular intra-hepatic portosystemic shunt (TIPS)

          -  Creatinine Clearance less than 10 ml/min or undergoing hemodialysis

          -  HIV infection

          -  Use of azole medications

          -  Pregnancy

          -  Current use of tolvaptan, hypertonic saline or other medical therapies for
             hyponatremia
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jasmohan S Bajaj, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hunter Holmes McGuire VA Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hunter Holmes McGuire VA Medical Center</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23249</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 15, 2012</study_first_submitted>
  <study_first_submitted_qc>March 15, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 16, 2012</study_first_posted>
  <last_update_submitted>February 6, 2014</last_update_submitted>
  <last_update_submitted_qc>February 6, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 7, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hunter Holmes Mcguire Veteran Affairs Medical Center</investigator_affiliation>
    <investigator_full_name>Jasmohan Bajaj</investigator_full_name>
    <investigator_title>Associate Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Cirrhosis</keyword>
  <keyword>Hepatic Encephalopathy</keyword>
  <keyword>Hyponatremia</keyword>
  <keyword>Brain MRI</keyword>
  <keyword>Health-related quality of life</keyword>
  <keyword>cognitive function</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Brain Diseases</mesh_term>
    <mesh_term>Hepatic Encephalopathy</mesh_term>
    <mesh_term>Hyponatremia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tolvaptan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

